QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone31-77-355-6600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.50 billion
Profitability
Miscellaneous
Employees4,688
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Qiagen (NYSE:QGEN) Frequently Asked Questions
What is Qiagen's stock symbol?
Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."
How were Qiagen's earnings last quarter?
Qiagen NV (NYSE:QGEN) issued its quarterly earnings data on Monday, February, 4th. The company reported $0.40 EPS for the quarter, meeting analysts' consensus estimates of $0.40. The firm had revenue of $403.20 million for the quarter, compared to analyst estimates of $409.32 million. Qiagen had a return on equity of 12.15% and a net margin of 12.68%. The company's revenue for the quarter was up 1.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.43 EPS. View Qiagen's Earnings History.
When is Qiagen's next earnings date?
What guidance has Qiagen issued on next quarter's earnings?
Qiagen updated its FY19 earnings guidance on Monday, February, 4th. The company provided earnings per share (EPS) guidance of $1.45-1.47 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.46. Qiagen also updated its FY 2019 guidance to $1.45-1.47 EPS.
What price target have analysts set for QGEN?
11 equities research analysts have issued 12-month price targets for Qiagen's stock. Their predictions range from $38.00 to $44.00. On average, they anticipate Qiagen's share price to reach $41.1667 in the next twelve months. This suggests a possible upside of 2.4% from the stock's current price. View Analyst Price Targets for Qiagen.
What is the consensus analysts' recommendation for Qiagen?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Qiagen.
Has Qiagen been receiving favorable news coverage?
News articles about QGEN stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Qiagen earned a news impact score of -1.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Qiagen's key competitors?
Some companies that are related to Qiagen include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX) and Aerie Pharmaceuticals (AERI).
What other stocks do shareholders of Qiagen own?
Who are Qiagen's key executives?
Qiagen's management team includes the folowing people:
- Mr. Peer Michael Schatz, CEO, MD & Member of Management Board (Age 53)
- Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 50)
- Dr. Barthold Piening, Sr. VP & Head of Global Operations (Age 61)
- Mr. John Gilardi, VP of Corp. Communications & Investor Relations
- Mr. Jean-Pascal Viola, Head of Corp. Bus. Devel., Intellectual Property & Litigation and Sr. VP
Who are Qiagen's major shareholders?
Qiagen's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (5.53%), BlackRock Inc. (2.90%), Hardman Johnston Global Advisors LLC (1.93%), Frontier Capital Management Co. LLC (1.16%), First Trust Advisors LP (1.10%) and Sycomore Asset Management (1.04%).
Which major investors are selling Qiagen stock?
QGEN stock was sold by a variety of institutional investors in the last quarter, including Carmignac Gestion, Legal & General Group Plc, SG Americas Securities LLC, Acadian Asset Management LLC, First Trust Advisors LP, Manning & Napier Group LLC, Los Angeles Capital Management & Equity Research Inc. and Castleark Management LLC.
Which major investors are buying Qiagen stock?
QGEN stock was acquired by a variety of institutional investors in the last quarter, including Sycomore Asset Management, American Century Companies Inc., Massachusetts Financial Services Co. MA, Millennium Management LLC, Jane Street Group LLC, BlackRock Inc., Bellevue Group AG and D. E. Shaw & Co. Inc..
How do I buy shares of Qiagen?
Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Qiagen's stock price today?
One share of QGEN stock can currently be purchased for approximately $40.22.
How big of a company is Qiagen?
Qiagen has a market capitalization of $9.07 billion and generates $1.50 billion in revenue each year. The company earns $190.38 million in net income (profit) each year or $1.34 on an earnings per share basis. Qiagen employs 4,688 workers across the globe.
What is Qiagen's official website?
How can I contact Qiagen?
Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912 PL. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]
MarketBeat Community Rating for Qiagen (NYSE QGEN)
MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
